186 related articles for article (PubMed ID: 18827262)
1. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Rondelli D
Haematologica; 2008 Oct; 93(10):1449-50. PubMed ID: 18827262
[No Abstract] [Full Text] [Related]
2. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
El Fakih R; Popat U
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S34-42. PubMed ID: 26297276
[TBL] [Abstract][Full Text] [Related]
3. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1350-1. PubMed ID: 17162218
[No Abstract] [Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia.
Hogan WJ; Litzow MR; Tefferi A
Curr Hematol Malig Rep; 2007 Feb; 2(1):34-42. PubMed ID: 20425386
[TBL] [Abstract][Full Text] [Related]
5. Advances in the understanding and management of primary myelofibrosis.
Cervantes F; Pereira A
Curr Opin Oncol; 2011 Nov; 23(6):665-71. PubMed ID: 21892083
[TBL] [Abstract][Full Text] [Related]
6. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.
Gupta V; Kröger N; Aschan J; Xu W; Leber B; Dalley C; Sabloff M; Lipton JH; Messner H; Brune M
Bone Marrow Transplant; 2009 Sep; 44(5):317-20. PubMed ID: 19234505
[No Abstract] [Full Text] [Related]
7. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Rosillo C; Camoriano JK
Am J Hematol; 2007 May; 82(5):400-2. PubMed ID: 17133423
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation as treatment for myelofibrosis.
Papageorgiou SG; Castleton A; Bloor A; Kottaridis PD
Bone Marrow Transplant; 2006 Dec; 38(11):721-7. PubMed ID: 17013423
[TBL] [Abstract][Full Text] [Related]
9. [Ruxolitinib as a bridge to allogeneic hematopoietic cell transplantation in a patient with idiopathic myelofibrosis].
Barba P; Fox ML; Blanco A; Valcárcel D
Med Clin (Barc); 2015 Feb; 144(4):184-5. PubMed ID: 24952663
[No Abstract] [Full Text] [Related]
10. [Non-myeloablative allogeneic hematopoietic stem cell transplantation for treatment of high-risk idiopathic myelofibrosis: a case report and literature review].
Yang J; Wang C; Cai Y
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):129-31. PubMed ID: 21429385
[No Abstract] [Full Text] [Related]
11. How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis.
Vannucchi AM
Leuk Res; 2009 Dec; 33(12):1581-3. PubMed ID: 19573914
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act.
Tefferi A
Bone Marrow Transplant; 2010 Mar; 45(3):419-21. PubMed ID: 20216545
[No Abstract] [Full Text] [Related]
13. Allogeneic stem cell transplantation for myelofibrosis in 2012.
McLornan DP; Mead AJ; Jackson G; Harrison CN
Br J Haematol; 2012 May; 157(4):413-25. PubMed ID: 22463701
[TBL] [Abstract][Full Text] [Related]
14. An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.
Adekola K; Popat U; Ciurea SO
Bone Marrow Transplant; 2014 Nov; 49(11):1352-9. PubMed ID: 25089599
[TBL] [Abstract][Full Text] [Related]
15. Balancing efficacy and safety of JAK inhibitors in myelofibrosis.
Passamonti F
Leuk Res; 2014 Mar; 38(3):290-1. PubMed ID: 24444869
[No Abstract] [Full Text] [Related]
16. Hypothesis: how do JAK2-inhibitors work in myelofibrosis.
Mesa R; Gale RP
Leuk Res; 2009 Sep; 33(9):1156-7. PubMed ID: 19450878
[TBL] [Abstract][Full Text] [Related]
17. [Molecular pathology and treatment for primary myelofibrosis].
Kitanaka A; Shimoda K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():321-5. PubMed ID: 23133975
[No Abstract] [Full Text] [Related]
18. Correction of recurrent angioedema related to C1 esterase inhibitor deficiency as a secondary event following nonmyeloablative allogeneic stem cell transplantation in a patient with myelofibrosis.
Kiss TL; Messner HA; Galal A; Lipton J
Bone Marrow Transplant; 2005 Jan; 35(2):213-4. PubMed ID: 15531899
[No Abstract] [Full Text] [Related]
19. Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.
Savani M; Dulery R; Bazarbachi AH; Mohty R; Brissot E; Malard F; Bazarbachi A; Nagler A; Mohty M
Br J Haematol; 2021 Nov; 195(4):495-506. PubMed ID: 33881169
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation for myelofibrosis: where are we now?
Fleischman AG; Maziarz RT
Curr Opin Hematol; 2013 Mar; 20(2):130-6. PubMed ID: 23314844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
